Rifaximin Again for IBS-D: What TARGET 3 Tested

If bowel symptoms return after a rifaximin course, take the treatment dates and symptom record to the prescribing review. Explain what improved, how long that lasted and what has returned. Those details matter when discussing another prescription.

Who entered the repeat-course comparison

TARGET 3 began with 2,579 people receiving open-label rifaximin. The randomized comparison enrolled initial responders who relapsed: 636 adults, including 441 women. This does not answer whether repeating treatment helps initial nonresponders. The manufacturer funded and analyzed the trial. Authors disclosed industry ties.¹

Patients received a two-week repeat course or placebo. The primary endpoint required at least 30% pain improvement and 50% fewer loose-stool days, together in at least two of the four weeks afterward.¹

What the response percentage means

The endpoint was met by 125/328 rifaximin recipients versus 97/308 placebo recipients: 38.1% versus 31.5%, P=.03. Weeks with insufficient diary data counted as nonresponse. Pain response differed significantly; the stool-consistency component alone did not.¹

Response did not require being symptom-free. Only three total courses were studied; years of retreatment remain uncertain.¹

A useful question for the appointment is: “Which returning symptom are we trying to change, and how will we measure it?” Keep pain, stool form and urgency as separate entries in your record. That makes a later review more specific than describing the whole month as better or worse.

How current guidance frames another course

The 2022 AGA guideline conditionally suggests retreatment for IBS-D after an initial response followed by recurrence, with moderate-certainty evidence. The panel cautions that improvements across several outcomes may be small and may not be clinically meaningful. A conditional recommendation leaves room for individual preferences and circumstances.²

Ask about the expected benefit alongside the prescription’s cost, prior side effects and the effort involved in another course. Agree on a review plan before starting, including what to do if the intended improvement does not occur.

Keep the prescription and safety review specific

The US Xifaxan label permits up to two repeat courses for recurrent IBS-D symptoms, using the same prescribed 14-day regimen. It does not provide an unlimited repeat-course schedule. Do not restart leftover tablets or transfer a regimen prescribed for another condition.³

The label warns about C. difficile-associated diarrhea and advises contacting a physician promptly if diarrhea develops after treatment, fails to improve or worsens during treatment. Returning diarrhea should therefore be discussed before assuming another IBS-D course is appropriate.³

Tell the prescriber about liver disease, pregnancy or pregnancy plans, rifamycin allergies and other medicines. The label calls for caution with severe liver impairment and cyclosporine, and for INR monitoring when rifaximin is used with warfarin. Ask the pharmacist to check the complete list before dispensing.³

Bloated by Dinner includes “The Visit Script,” which recommends recording symptom timing and stool form, listing medicines and supplements, and asking what has been ruled out and what comes next.